Sign In
Buy AMGN
$345.60
+7.38 (+2.18%)
At Close: Jun 04, 2026
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
10:02am, Tuesday, 01'st Oct 2024
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE
09:00am, Tuesday, 01'st Oct 2024
Campaign Encourages Open Dialogue With Doctor About Unmanaged Symptoms to Find the Right Treatment Option THOUSAND OAKS, Calif. , Oct. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) has partnered with
Prescription For Dividends: Why Amgen Is More Than Just A Safe Bet
01:32am, Monday, 30'th Sep 2024
Amgen's strong dividend growth, with a 2.8% yield and consistent hikes since 2011, offers reliable income and a healthy payout ratio. Robust R&D pipeline in obesity, cardiovascular, and oncology, alon
Amgen (AMGN) Ascends While Market Falls: Some Facts to Note
06:56pm, Friday, 27'th Sep 2024
Amgen (AMGN) closed at $322.67 in the latest trading session, marking a +1.12% move from the prior day.
Federman & Sherwood Investigates Amgen, Inc. for Data Breach
04:35pm, Friday, 27'th Sep 2024
OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Amgen, Inc. for Data Breach.
Calls of the Day: Salesforce, Walmart, Pepsico and Amgen
01:26pm, Friday, 27'th Sep 2024
The Investment Committee debate the latest Calls Of The Day.
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why
12:41pm, Thursday, 26'th Sep 2024
Though Amgen reported encouraging results on two immunology drugs, Wall Street expresses skepticism as the data fell short when compared to existing treatments.
Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
09:15am, Thursday, 26'th Sep 2024
Amgen's shares fell this week despite positive phase 3 results of rocatinlimab and Uplizna. Rocatinlimab's phase 3 results were disappointing, as efficacy well short of its competitors and it also und
Amgen's stock falls 4% as analysts say drug updates lag competitors
02:00pm, Wednesday, 25'th Sep 2024
The biotech offered an update on two drugs in development, but analysts said they're not as effective as existing treatments.
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
01:30pm, Wednesday, 25'th Sep 2024
In an investor update on Tuesday, Amgen Inc AMGN released data from Phase 3 trials of rocatinlimab and Uplizna (inebilizumab).
Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
08:00am, Wednesday, 25'th Sep 2024
Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio, including Eylea, Dupixent, and Libtayo, and a robust investigational pipeline. Despite legal setbacks from Amgen's Eylea bi
Amgen's experimental skin disease drug meets main goals in study
04:58pm, Tuesday, 24'th Sep 2024
Amgen said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment for a skin condition known as atopic dermatitis.
TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE
04:00pm, Tuesday, 24'th Sep 2024
THOUSAND OAKS, Calif. , Sept. 24, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
02:11pm, Tuesday, 24'th Sep 2024
A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar.
2 Weight-Loss Stocks That Could Rocket Higher This Year
04:57am, Tuesday, 24'th Sep 2024
Injections that help folks manage their appetite already generate over $45 billion in annual revenue. Total sales of weight-management drugs are expected to reach $100 billion annually by 2030.
